Cover Image
市場調查報告書

生物模擬的全球市場預測 2022年:各產品、用途,提供方式,終端用戶

Biosimulation Market by Product (Software, Molecular Simulation, In House, Contract Services), Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, CRO, Regulatory) - Global Forecast to 2022

出版商 MarketsandMarkets 商品編碼 336606
出版日期 內容資訊 英文 182 Pages
訂單完成後即時交付
價格
Back to Top
生物模擬的全球市場預測 2022年:各產品、用途,提供方式,終端用戶 Biosimulation Market by Product (Software, Molecular Simulation, In House, Contract Services), Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, CRO, Regulatory) - Global Forecast to 2022
出版日期: 2018年01月03日 內容資訊: 英文 182 Pages
簡介

全球生物模擬市場,預計2017年達13億8000萬美元,2022年達28億8000萬美元,以15.9%的年複合成長率 (CAGR) 成長。各產品與服務生物模擬服務多數成長,運用方式自家公司持有方式獨佔市場。

本報告提供全球生物模擬市場相關調查,市場概要,主要的促進要素,阻礙要素,機會及課題的相關分析,各用途、終端用戶、地區的市場規模與收益預測,市場佔有率預測,及主要企業簡介等彙整,為您概述為以下內容。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

第5章 市場概要

  • 簡介
  • 市場動態
    • 促進要素
      • 在製藥、生物科技產業的研究開發 (R&D) 投資額的增加
      • 在法規團體的生物模擬、軟體的引進增加
      • 技術進步型的QSP (定量的系統藥理學) 系統
      • 藥物研發、臨床實驗成本的抑制需求
      • 生技藥品、生物相似藥市場成長
    • 阻礙要素
      • 缺乏標準化
    • 機會
      • 新的用途
      • 個人化醫療的利用擴大
      • 兒童用藥物的開發用,生物模擬、解決方案的利用
    • 課題
      • 讓生技藥品的複雜系統匹配流程的困難
      • 生物模擬、建模的專家不足

第6章 生物模擬市場:各產品與服務

  • 簡介
  • 軟體
    • PK/PD建模、模擬軟體
    • 粒子建模、模擬軟體
    • PBPK (生理學的藥物動力學) 建模、模擬軟體
    • 毒性預測軟體
    • 臨床實驗設計用軟體
    • 其他的生物模擬用軟體
  • 服務
    • 公司內部服務
    • 外部委託服務

第7章 生物模擬市場:各用途

  • 簡介
  • 藥物開發
    • 臨床試驗前
      • PK/PD (藥物動力學/藥效學)
      • ADME/Tox (吸收、分佈、代謝、排泄/毒性) 實驗
    • 臨床實驗
  • 藥物研發
    • 標的鑑別、評估
    • 先導藥物的鑑別與最佳化
  • 其他的用途

第8章 生物模擬市場:各提供模式

  • 簡介
  • 訂閱模式
  • 擁有模式

第9章 生物模擬市場:各終端用戶

  • 簡介
  • 製藥企業,生物科技企業
  • 研究機關
  • CRO (臨床研究委外機構)
  • 法規當局
  • 其他

第10章 生物模擬市場:各地區

  • 簡介
  • 北美 (美國,加拿大)
  • 歐洲 (德國,英國,法國等)
  • 亞洲
  • 其他的國家 (RoW)

第11章 競爭環境

  • 概要
  • 市場排行榜分析
  • 競爭方案
    • 產品上市、認證
    • 協定,事業協定、合作
    • 企業收購
    • 事業擴張

第12章 企業簡介

  • CERTARA
  • SIMULATION PLUS
  • DASSAULT SYSTEMES
  • SCHRODINGER
  • ADVANCED CHEMISTRY DEVELOPMENT
  • CHEMICAL COMPUTING GROUP
  • ROSA
  • GENEDATA
  • PHYSIOMICS
  • EVIDERA
  • IN SILICO BIOSCIENCES
  • LEADINVENT TECHNOLOGIES
  • INOSIM SOFTWARE
  • NUVENTRA PHARMA
  • INSILICO BIOTECHNOLOGY

第13章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HIT 3629

"Global biosimulation market projected to grow at a CAGR of 15.9%"

The biosimulation market is expected to reach USD 2.88 billion by 2022 from USD 1.38 billion in 2017, at a CAGR of 15.9%. Increase in R&D investments in the pharmaceutical and biotechnology industries, growing adoption of biosimulation software by regulatory bodies, technologically advanced QSP systems, need to curtail drug discovery and development costs, and growth in the biologics and biosimilars markets are driving the growth of the biosimulation market. On the other hand, market growth may be limited to a certain extent due to the lack of standardization for biosimulation solutions.

"Biosimulation services are expected to grow at the highest CAGR during the forecast period"

By product and service, the biosimulation market is segmented into software and services. The biosimulation services segment is projected to register the highest CAGR during the forecast period. The high growth in this segment is attributed to the recurring need for services such as data analysis, and consulting services.

"Ownership models segment is expected to dominate the market during the forecast period"

Based on the delivery model, the biosimulation market is segmented into ownership models and subscription models. The ownership models segment is expected to dominate the market during the forecast period. Buyers mainly opt for these delivery models due to the security benefits associated with them are the major factors that are supporting the growth of this delivery models segment.

"Europe to witness high growth during the forecast period"

In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Europe is expected to register the highest CAGR during the forecast period. The growing focus on research-related funding activities by governments is expected to assist in the development of drug discovery and development process, thus driving the demand for biosimulation in the European region.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 62%; Tier 2 - 25%; Tier 3 - 13%.
  • By Designation: C-level- 29%; D-level- 25%; Others-46%.
  • By Region: North America-55%; Europe-24%; Asia-15%; RoW-6%.

List of companies profiled in the report:

  • Certara (US)
  • Simulations Plus (US)
  • Dassault Systemes (France)
  • Schrodinger (US)
  • ACD/Labs (Canada)
  • Chemical Computing Group (Canada)
  • Physiomics (UK)
  • Evidera (US)
  • In silico biosciences (US)
  • INOSIM Software (Germany)
  • Insilico Biotechnology (Germany)
  • LeadInvent Technologies (India)
  • Rosa (US)
  • Nuventra Pharma (US)
  • Genedata (Switzerland)ssss

Research Coverage:

The report provides an overview of the biosimulation market. It aims at estimating the market size and future growth potential of this market across different segments such as product & service, applications, delivery model, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall biosimulation market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 MARKET STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 SECONDARY DATA
    • 2.2.1 SECONDARY SOURCE
  • 2.3 PRIMARY DATA
    • 2.3.1 PRIMARY SOURCES
    • 2.3.2 KEY INDUSTRY INSIGHTS
  • 2.4 MARKET SIZE ESTIMATION
  • 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.6 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 BIOSIMULATION MARKET OVERVIEW
  • 4.2 BIOSIMULATION SOFTWARE MARKET, BY TYPE
  • 4.3 GEOGRAPHIC ANALYSIS: BIOSIMULATION MARKET IN EUROPE,

BY END USER AND COUNTRY 33

  • 4.4 BIOSIMULATION DRUG DEVELOPEMENT MARKET, BY TYPE

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increase in R&D investments in the pharmaceutical and biotechnology industries
      • 5.2.1.2 Growing adoption of biosimulation software by regulatory bodies
      • 5.2.1.3 Technologically advanced QSP systems
      • 5.2.1.4 Need to curtail drug discovery and development costs
      • 5.2.1.5 Growth in the biologics and biosimilars markets
    • 5.2.2 RESTRAINT
      • 5.2.2.1 Lack of standardization
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging applications
      • 5.2.3.2 Increased use of personalized medicine
      • 5.2.3.3 Use of biosimulation solution for pediatric drug development
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Difficulty in matching the complexity of biological systems and processes
      • 5.2.4.2 Shortage of biosimulation and modeling experts

6 BIOSIMULATION MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
  • 6.2 SOFTWARE
    • 6.2.1 PK/PD MODELING AND SIMULATION SOFTWARE
    • 6.2.2 MOLECULAR MODELING AND SIMULATION SOFTWARE
    • 6.2.3 PBPK MODELING AND SIMULATION SOFTWARE
    • 6.2.4 TOXICITY PREDICTION SOFTWARE
    • 6.2.5 TRIAL DESIGN SOFTWARE
    • 6.2.6 OTHER BIOSIMULATION SOFTWARE
  • 6.3 SERVICES
    • 6.3.1 IN-HOUSE SERVICES
    • 6.3.2 CONTRACT SERVICES

7 BIOSIMULATION MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 DRUG DEVELOPMENT
    • 7.2.1 PRECLINICAL TESTING
      • 7.2.1.1 PK/PD
      • 7.2.1.2 ADME/Tox
    • 7.2.2 CLINICAL TRIALS
  • 7.3 DRUG DISCOVERY
    • 7.3.1 TARGET IDENTIFICATION AND VALIDATION
    • 7.3.2 LEAD IDENTIFICATION AND OPTIMIZATION
  • 7.4 OTHER APPLICATIONS

8 BIOSIMULATION MARKET, BY DELIVERY MODEL

  • 8.1 INTRODUCTION
  • 8.2 SUBSCRIPTION MODELS
  • 8.3 OWNERSHIP MODELS

9 BIOSIMULATION MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.3 RESEARCH INSTITUTES
  • 9.4 CONTRACT RESEARCH ORGANIZATIONS
  • 9.5 REGULATORY AUTHORITIES
  • 9.6 OTHER END USERS

10 BIOSIMULATION MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 US
    • 10.2.2 CANADA
  • 10.3 EUROPE
    • 10.3.1 GERMANY
    • 10.3.2 UK
    • 10.3.3 FRANCE
    • 10.3.4 REST OF EUROPE (ROE)
  • 10.4 ASIA
  • 10.5 REST OF THE WORLD (ROW)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 MARKET RANKING ANALYSIS, 2016
  • 11.3 COMPETITIVE SCENARIO
    • 11.3.1 PRODUCT LAUNCHES AND APPROVALS
    • 11.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 11.3.3 ACQUISITIONS
    • 11.3.4 EXPANSIONS

12 COMPANY PROFILES

(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*

  • 12.1 CERTARA
  • 12.2 SIMULATION PLUS
  • 12.3 DASSAULT SYSTEMES
  • 12.4 SCHRODINGER
  • 12.5 ADVANCED CHEMISTRY DEVELOPMENT
  • 12.6 CHEMICAL COMPUTING GROUP
  • 12.7 ROSA
  • 12.8 GENEDATA
  • 12.9 PHYSIOMICS
  • 12.10 EVIDERA
  • 12.11 IN SILICO BIOSCIENCES
  • 12.12 LEADINVENT TECHNOLOGIES
  • 12.13 INOSIM SOFTWARE
  • 12.14 NUVENTRA PHARMA
  • 12.15 INSILICO BIOTECHNOLOGY

Details on MarketsandMarkets view, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 INSIGHTS FORM INDUSTRY EXPERTS
  • 13.2 DISCUSSION GUIDE
  • 13.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5 AVAILABLE CUSTOMIZATIONS
  • 13.6 RELATED REPORTS
  • 13.7 AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 2: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 3: BIOSIMULATION SOFTWARE MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 4: NORTH AMERICA: BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 5: EUROPE: BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 6: PK/PD MODELING AND SIMULATION SOFTWARE MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 7: NORTH AMERICA: PK/PD MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 8: EUROPE: PK/PD MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 9: MOLECULAR MODELING AND SIMULATION SOFTWARE MARKET, BY REGION, 2015-2022 (USD MILLION
  • TABLE 10: NORTH AMERICA: MOLECULAR MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 11: EUROPE: MOLECULAR MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 12: PBPK MODELING AND SIMULATION SOFTWARE MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 13: NORTH AMERICA: PBPK MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 14: EUROPE: PBPK MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 15: TOXICITY PREDICTION SOFTWARE MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 16: NORTH AMERICA: TOXICITY PREDICTION SOFTWARE MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 17: EUROPE: TOXICITY PREDICTION SOFTWARE MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 18: TRIAL DESIGN SOFTWARE MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 19: NORTH AMERICA: TRIAL DESIGN SOFTWARE MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 20: EUROPE: TRIAL DESIGN SOFTWARE MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 21: OTHER BIOSIMULATION SOFTWARE MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 22: NORTH AMERICA: OTHER BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 23: EUROPE: OTHER BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 24: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 25: BIOSIMULATION SERVICES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 26: NORTH AMERICA: BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 27: EUROPE: BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 28: IN-HOUSE BIOSIMULATION SERVICES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 29: NORTH AMERICA: IN-HOUSE BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 30: EUROPE: IN-HOUSE BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 31: CONTRACT BIOSIMULATION SERVICES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 32: NORTH AMERICA: CONTRACT BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 33: EUROPE: CONTRACT BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 34: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 35: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 36: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 37: NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 38: EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 39: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 40: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY REGION, 2015-2022 (USD MILLION )
  • TABLE 41: NORTH AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 42: EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 43: BIOSIMULATION MARKET FOR PK/PD, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 44: NORTH AMERICA: BIOSIMULATION MARKET FOR PK/PD, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 45: EUROPE: BIOSIMULATION MARKET FOR PK/PD, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 46: BIOSIMULATION MARKET FOR ADME/TOX, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 47: NORTH AMERICA: BIOSIMULATION MARKET FOR ADME/TOX, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 48: EUROPE: BIOSIMULATION MARKET FOR ADME/TOX, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 49: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 50: NORTH AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 51: EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 52: BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY TYPE, 2015-2022 (USD MILLION )
  • TABLE 53: BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 54: NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 55: EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 56: BIOSIMULATION MARKET FOR TARGET IDENTIFICATION AND OPTIMIZATION, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 57: NORTH AMERICA: BIOSIMULATION MARKET FOR TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 58: EUROPE: BIOSIMULATION MARKET FOR TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 59: BIOSIMULATION MARKET FOR LEAD IDENTIFICATION AND OPTIMIZATION, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 60: NORTH AMERICA: BIOSIMULATION MARKET FOR LEAD IDENTIFICATION AND OPTIMIZATION, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 61: EUROPE: BIOSIMULATION MARKET FOR LEAD IDENTIFICATION AND OPTIMIZATION, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 62: BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2015-2022 (USD MILLION )
  • TABLE 63: NORTH AMERICA: BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 64: EUROPE: BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 65: GLOBAL BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015-2022 (USD MILLION)
  • TABLE 66: GLOBAL BIOSIMULATION MARKET FOR SUBSCRIPTION MODELS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 67: NORTH AMERICA: BIOSIMULATION MARKET FOR SUBSCRIPTION MODELS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 68: EUROPE: BIOSIMULATION MARKET FOR SUBSCRIPTION MODELS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 69: GLOBAL BIOSIMULATION MARKET FOR OWNERSHIP MODELS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 70: NORTH AMERICA: BIOSIMULATION MARKET FOR OWNERSHIP MODELS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 71: EUROPE: BIOSIMULATION MARKET FOR OWNERSHIP MODELS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 72: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 73: BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 74: NORTH AMERICA: BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 75: EUROPE: BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 76: BIOSIMULATION MARKET FOR RESEARCH INSTITUTES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 77: NORTH AMERICA: BIOSIMULATION MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 78: EUROPE: BIOSIMULATION MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 79: BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 80: NORTH AMERICA: BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 81: EUROPE: BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 82: BIOSIMULATION MARKET FOR REGULATORY AUTHORITIES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 83: NORTH AMERICA: BIOSIMULATION MARKET FOR REGULATORY AUTHORITIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 84: EUROPE: BIOSIMULATION MARKET FOR REGULATORY AUTHORITIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 85: BIOSIMULATION MARKET FOR OTHER END USERS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 86: NORTH AMERICA: BIOSIMULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 87: EUROPE: BIOSIMULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 88: BIOSIMULATION MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 89: NORTH AMERICA BIOSIMULATION MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 90: NORTH AMERICA: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 91: NORTH AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 92: NORTH AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 93: NORTH AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 94: NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 95: NORTH AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 96: NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 97: NORTH AMERICA: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015-2022 (USD MILLION)
  • TABLE 98: NORTH AMERICA: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 99: US: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 100: US: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 101: US: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 102: US: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 103: US: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 104: US: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 105: US: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 106: US: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015-2022 (USD MILLION)
  • TABLE 107: US: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 108: CANADA: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 109: CANADA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 110: CANADA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 111: CANADA: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 112: CANADA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 113: CANADA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 114: CANADA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 115: CANADA: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015-2022 (USD MILLION)
  • TABLE 116: CANADA: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 117: EUROPE: PHARMACEUTICAL R&D EXPENDITURE, BY COUNTRY, 2015
  • TABLE 118: EUROPE: BIOSIMULATION MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 119: EUROPE: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 120: EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 121: EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 122: EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 123: EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 124: EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 125: EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 126: EUROPE: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015-2022 (USD MILLION)
  • TABLE 127: EUROPE: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 128: BIOTECHNOLOGY INDUSTRY IN GERMANY (2009 VS. 2016)
  • TABLE 129: GERMANY: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 130: GERMANY: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 131: GERMANY: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 132: GERMANY: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 133: GERMANY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 134: GERMANY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 135: GERMANY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 136: GERMANY: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015-2022 (USD MILLION)
  • TABLE 137: GERMANY: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 138: UK: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 139: UK: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 140: UK: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 141: UK: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 142: UK: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 143: UK: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 144: UK: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 145: UK: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015-2022 (USD MILLION)
  • TABLE 146: UK: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 147: FRANCE: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 148: FRANCE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 149: FRANCE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 150: FRANCE: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 151: FRANCE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 152: FRANCE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 153: FRANCE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 154: FRANCE: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015-2022 (USD MILLION)
  • TABLE 155: FRANCE: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 156: ROE: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 157: ROE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 158: ROE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 159: ROE: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 160: ROE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 161: ROE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 162: ROE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 163: ROE: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015-2022 (USD MILLION)
  • TABLE 164: ROE: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 165: ASIA: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 166: ASIA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 167: ASIA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 168: ASIA: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 169: ASIA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 170: ASIA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 171: ASIA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 172: ASIA: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015-2022 (USD MILLION)
  • TABLE 173: ASIA: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 174: ROW: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 175: ROW: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 176: ROW: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 177: ROW: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 178: ROW: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 179: ROW: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 180: ROW: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 181: ROW: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015-2022 (USD MILLION)
  • TABLE 182: ROW: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 183: RANK OF COMPANIES IN THE GLOBAL BIOSIMULATION MARKET, 2016
  • TABLE 184: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 185: AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
  • TABLE 186: ACQUISITIONS
  • TABLE 187: EXPANSIONS

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN: BIOSIMULATION MARKET
  • FIGURE 2: BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION
  • FIGURE 3: MARKET ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 4: GLOBAL MARKET SIZE OF THE BIOSIMULATION MARKET: TOP-DOWN APPROACH
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: BIOSIMULATION SOFTWARE TO DOMINATE THE BIOSIMULATION MARKET IN 2017 AND 2022
  • FIGURE 7: DRUG DEVELOPMENT SEGMENT TO DOMINATE THE BIOSIMULATION APPLICATIONS MARKET IN 2017 AND 2022
  • FIGURE 8: SUBSCRIPTION MODEL SEGMENT TO DOMINATE THE DELIVERY MODEL SEGMENT OF BIOSIMULATION MARKET IN 2017 AND 2022
  • FIGURE 9: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE THE BIOSIMULATION END-USER MARKET
  • FIGURE 10: EUROPE TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD (2017-2022)
  • FIGURE 11: INCREASE IN R&D INVESTMENTS IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES TO DRIVE THE GROWTH OF THE MARKET
  • FIGURE 12: PK/PD MODELING AND SIMULATION SOFTWARE TO ACCOUNT FOR THE LARGEST MARKET SIZE IN 2017 AND 2022
  • FIGURE 13: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOSIMULATION MARKET IN EUROPE IN 2017
  • FIGURE 14: PRECLINICAL TESTING TO WITNESS HIGH GROWTH FROM 2017 TO 2022
  • FIGURE 15: BIOSIMULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 16: SOFTWARE SEGMENT TO DOMINATE THE BIOSIMULATION MARKET IN 2017
  • FIGURE 17: DRUG DEVELOPMENT SEGMENT TO DOMINATE THE BIOSIMULATION MARKET DURING THE FORECAST PERIOD
  • FIGURE 18: OWNERSHIP MODELS SEGMENT TO OFFER SIGNIFICANT GROWTH OPPORTUNITIES DURING THE FORECAST PERIOD
  • FIGURE 19: BIOSIMULATION MARKET, BY END USER, 2017 VS. 2022 (USD MILLION)
  • FIGURE 20: BIOSIMULATION MARKET IN EUROPE TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 21: NORTH AMERICA: BIOSIMULATION MARKET SNAPSHOT
  • FIGURE 22: EUROPE: BIOSIMULATION MARKET SNAPSHOT
  • FIGURE 23: ASIA: BIOSIMULATION MARKET SNAPSHOT
  • FIGURE 24: ROW: BIOSIMULATION MARKET SNAPSHOT
  • FIGURE 25: MARKET EVOLUTION FRAMEWORK
  • FIGURE 26: SIMULATION PLUS: COMPANY SNAPSHOT (2016)
  • FIGURE 27: DASSAULT SYSTEMES: COMPANY SNAPSHOT (2016)
  • FIGURE 28: PHYSIOMICS : COMPANY SNAPSHOT (2017)
Back to Top